Skip to main content
Advertisement
Live broadcast
Main slide
Beginning of the article
Озвучить текст
Select important
On
Off

August is Spinal Muscular Atrophy (SMA) Awareness Month. This is a rare disease, which in recent years has become one of the most "media" among orphan diseases. This was not least due to the medical revolution: drugs appeared that made it possible to stop the course of a deadly disease and significantly improve the quality of life of patients. However, this revolution is not cheap: drugs for the treatment of SMA are among the most expensive in the world, and people suffering from this disease cannot purchase them on their own. Izvestia investigated how science has changed the lives of children with spinal muscular atrophy and how medicines are available to all patients in Russia.

How many people with SMA in Russia

According to estimates by the SMA Family Foundation, there are more than 1.5 thousand patients with this disease in Russia, of which more than 1 thousand are children. That's not a small number. Among orphan diseases, spinal muscular atrophy is one of the most widespread after cystic fibrosis (4.5 thousand patients) and Duchenne muscular dystrophy (about 2 thousand).

Младенец
Photo: IZVESTIA/Sergey Lantyukhov

The frequency of SMA is approximately one case per 7-8 thousand newborns, says Evgenia Uvakina, head of the Department of Neuropsychiatry and Neurorehabilitation at the National Research Medical Center for Children's Health of the Russian Ministry of Health.

— The carrier statistics are much more impressive: every 36th Russian carries mutations in the SMN1 gene. Thus, if 40 adults are sitting in a room, it is highly likely that one of them is a carrier of SMA. If two such carriers meet, the risk of having a sick child in each pregnancy is 25%," she told Izvestia.

Родильный дом
Photo: IZVESTIA/Sergey Lantyukhov

At the same time, it can also be said that SMA is perhaps the most famous orphan disease.

— I would say that this is one of the most "media—related" diseases, - confirms Anastasia Baykina, General Director of the Important People Charitable Foundation. — There are specific things behind this: the strongest patient community, popular fees, as well as the status of SMA as the first rare disease with gene therapy and the first diagnosis in the Circle of Goodness procurement. This is a rare case when public activism has really changed the care system.

The Drug Revolution

Another reason for this "popularity" is obviously that it was in the treatment of this disease that the drug revolution took place. Until the mid-2010s, patients with SMA could not actually hope for a high-quality and long life. With spinal muscular atrophy, motor neurons are gradually destroyed, they are also alpha-motor neurons, cells of the spinal cord responsible for movement.

— Motor neurons need a specific protein called SMN (Survival Motor Neuron) to function. Normally, it is produced by the main SMN1 gene. In patients with SMA, sections of this gene are missing or damaged," explains Evgenia Uvakina. — The body is trying to compensate for the lack of SMN protein with the help of a "spare" gene, SMN2, but 90% of the protein it produces is unstable and quickly degrades. The remaining 10% of neurons are sorely lacking: they begin to die en masse and stop signaling the muscles.

Капельница
Photo: IZVESTIA/Sergey Lantyukhov

As a result, the muscles weaken and atrophy. A person gradually stops walking, using his hands, cannot swallow or even breathe. Previously, it was impossible to stop this process.

In the most severe form of SMA (type 0), patients died in the first days of life. In the most common type I case, up to 60% of diagnosed cases, symptoms appeared before the age of six months, and without therapy, children died before the age of two. In type II, which starts in children under 18 months of age, patients are usually able to sit but not walk on their own. Types III and IV of SMA are late, they make their debut between the ages of 18 months and 30 years. Patients can usually walk, but over time they often lose this skill.

Previously, treatment was only supportive: feeding through a probe, infection prevention, artificial ventilation.

ИВЛ
Photo: IZVESTIA/Dmitry Korotaev

In December 2016, the world's first drug for the pathogenetic therapy of SMA appeared: nusinersen, better known as Spinraza. This drug (like Risdiplam, which entered the market in 2020, also known as Eurisdy) causes the SMN2 gene to produce the protein in the required volume.

Treatment is lifelong: Spinraza is injected into the spinal canal several times a year, and Risdiplam is taken orally in the form of a solution. The SMA Family Foundation told Izvestia that there are already pills that will significantly simplify the lives of patients, but the drug is not yet available in Russia in this form, as are the increased dosages of Spinraza approved for use in the United States and Europe. Although the demand for this in the patient community is quite high, said Olga Germanenko, founder and director of the foundation.

But perhaps the biggest breakthrough came in May 2019. At that time, a drug for gene therapy was registered: onasemnogen abeparvovek, aka "Zolgensma". The medicine is administered once in a lifetime, but so far only to young children.

—Gene therapy works on the principle of substitution: a working copy of the missing SMN1 gene is introduced into the cells of the body using a safe viral vector, after which they are able to independently produce the necessary protein on an ongoing basis," explains Evgenia Uvakina.

Ампулы
Photo: IZVESTIA/Eduard Kornienko

All three drugs are registered in Russia. At the same time, in 2024, the first Russian equivalent of nucenersen appeared — Lantesens, which is successfully used throughout the country, says the interlocutor of Izvestia. Risdiplam generics are also at the registration stage, clinical trials and a Russian gene therapy drug are underway.

In the very near future, there may be a drug that will be available to adolescents and adults. In addition, drugs capable of providing muscle growth and strength are being developed.

Children of the "golden therapeutic window"

In 2023, SMA was included in the Russian expanded neonatal screening program. Now, on the second day of life, children are checked for the presence of this genetic disease.

According to the Medical and Genetic Research Center named after Academician N.P. Bochkov (MGNC), more than 450 children with spinal muscular atrophy have been identified at the preclinical stage since the launch of expanded neonatal screening. Examination of newborns allows you to enter the "golden therapeutic window".

Врач
Photo: IZVESTIA/Sergey Lantyukhov

Dmitry Vlodavets, head of the Children's Scientific and Practical Center for Neuromuscular Pathology at the Scientific Research Clinical Institute of Pediatrics named after Academician Yu.E. Veltischev, notes in an interview with Izvestia that if a diagnosis is detected in the first days of life, therapy starts literally in a matter of weeks.

— If you start treatment on time, the motor neurons in the spinal cord will not be affected. Babies will not have any manifestations of spinal muscular atrophy, they will grow up to be healthy, full—fledged members of society," he emphasizes.

There are already more than 150 children with SMA in Russia who received treatment before the onset of symptoms, says Evgenia Uvakina. These patients are being closely monitored: the mutation in the SMN1 gene has not gone away, and therapy has been available for less than 10 years, so long-term results are not known. But so far it is impossible to distinguish such guys from ordinary children. And this is a new reality: an asymptomatic course of the disease has never been noted before. This, by the way, may lead to a new classification of SMA, depending on the preserved motor functions.

Игрушка
Photo: IZVESTIA/Dmitry Korotaev

In children whose treatment began after the onset of symptoms, it is possible to stop the development of the disease, but not to revive the dead neurons: young patients still have varying degrees of muscle weakness. However, SMA has ceased to be a fatal disease: now it is more of a manageable chronic condition. The main task of doctors now is to ensure that a child is able to work and independent in 20 years.

Is everyone receiving therapy

Perhaps the main problem of modern therapy is its cost. The drug "Zolgensma" has long been one of the most expensive in the world — one injection cost $ 2 million.

Since 2021, the presidential foundation Circle of Goodness has been providing children with the necessary drugs in Russia. The press service of the Ministry of Health informed Izvestia that during the operation of this fund, more than 1.8 thousand SMA patients received treatment, of which, according to the MGNC, 439 received gene therapy. Olga Germanenko noted that Russia has created one of the best systems in the world for children with spinal muscular atrophy.

Палата
Photo: IZVESTIA/Eduard Kornienko

For adults, the situation is more complicated: SMA is not included in any of the government programs, and people suffering from this disease have the right to receive the drug only from the regional budget, which is often fraught with difficulties, especially in poor regions of the Russian Federation. The proportion of adult patients receiving therapy has increased significantly in recent years, but has not yet reached 100%: according to Olga Germanenko, about 82% of them are provided with drug treatment. Coverage is comparable to that of developed countries, although lower than in the United States and several European countries. In addition, over the past year and a half, the foundation has seen increased cases of interruptions in providing patients with drugs, which is why they do not receive treatment promptly, and this happens in a wide variety of regions, even in the prosperous Moscow region.

Another major problem in the treatment of adults, the editorial's interlocutor calls the need to register a disability in order to provide medicines.

— There are patients with fairly well—preserved forms who retain the ability to walk, work independently, etc., - Olga Germanenko draws attention. — We have had several cases where people had to quit their jobs in order to start treatment. And for young adults who previously received medications from the Circle of Goodness, it can be psychologically difficult to acquire a disability.

Руки матери и ребенка
Photo: IZVESTIA/Polina Violet

The problem, according to the expert, will worsen, because more and more children without disabilities will begin to leave the care of the Circle of Goodness and will be faced with the need to register a disability in order to continue receiving expensive treatment at the expense of regional budgets. Therefore, the SMA Families insist that drug provision be untied from disability and provided upon the presence of a disease, as is the case with orphan diseases included in the list of rare life-threatening diseases by Decree of the Government of the Russian Federation No. 403.

At the same time, the help does not end with therapy.: this is just the foundation. Maria Sergeeva, a neurologist at the Clinical Diagnostic Center of the NMIC of Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation, emphasizes that with an already formed neurological deficit, rehabilitation plays a leading role in maintaining the functional activity of patients with SMA - it can increase the duration and quality of life of patients, improve functional and social status.

Больница
Photo: IZVESTIA/Sergey Lantyukhov

We are talking specifically about access to multidisciplinary care: physical rehabilitation, monitoring by diverse specialists, and obtaining high-tech technical equipment (TSR).

Doctors, however, note that there is "progress on this issue, too." Rehabilitation methods adapted to different types of SMA and stages of the disease are actively developing, says Dmitry Vlodavets. The focus is on helping patients maintain and develop motor skills, even if some of the functions have already been lost.

The main task now, according to Olga Germanenko, is to ensure that patients with spinal muscular atrophy can receive multiprofessional care regardless of which region each of them lives in. But so far, such a system is just beginning to take shape.

Переведено сервисом «Яндекс Переводчик»

Live broadcast